- Home
- Publications
- Publication Search
- Publication Details
Title
Biologics in inflammatory bowel disease: what are the data?
Authors
Keywords
-
Journal
United European Gastroenterology Journal
Volume 3, Issue 5, Pages 419-428
Publisher
SAGE Publications
Online
2015-06-10
DOI
10.1177/2050640615590302
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Effects of Vedolizumab Induction Therapy for Patients With Crohn’s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed
- (2014) Bruce E. Sands et al. GASTROENTEROLOGY
- Subcutaneous Golimumab Induces Clinical Response and Remission in Patients With Moderate-to-Severe Ulcerative Colitis
- (2013) William J. Sandborn et al. GASTROENTEROLOGY
- Methotrexate in Combination With Infliximab Is No More Effective Than Infliximab Alone in Patients With Crohn's Disease
- (2013) Brian G. Feagan et al. GASTROENTEROLOGY
- Combination Therapy With Infliximab and Azathioprine Is Superior to Monotherapy With Either Agent in Ulcerative Colitis
- (2013) Remo Panaccione et al. GASTROENTEROLOGY
- Subcutaneous Golimumab Maintains Clinical Response in Patients With Moderate-to-Severe Ulcerative Colitis
- (2013) William J. Sandborn et al. GASTROENTEROLOGY
- Efficacy and safety of adalimumab in Japanese patients with moderately to severely active ulcerative colitis
- (2013) Yasuo Suzuki et al. JOURNAL OF GASTROENTEROLOGY
- Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
- (2013) Brian G. Feagan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
- (2013) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Clinical effects of adalimumab treatment with concomitant azathioprine in Japanese Crohn’s disease patients
- (2013) Kumi Ishida WORLD JOURNAL OF GASTROENTEROLOGY
- Does co-treatment with immunosuppressors improve outcome in patients with Crohn's disease treated with adalimumab?
- (2012) C. Reenaers et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Adalimumab Induces and Maintains Mucosal Healing in Patients With Crohn's Disease: Data From the EXTEND Trial
- (2012) Paul Rutgeerts et al. GASTROENTEROLOGY
- Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol
- (2012) Xavier Hébuterne et al. GUT
- Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial
- (2012) David Laharie et al. LANCET
- Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease
- (2012) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis
- (2011) William J. Sandborn et al. GASTROENTEROLOGY
- Adalimumab for induction of clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial
- (2011) W. Reinisch et al. GUT
- Adalimumab for the induction and maintenance of clinical remission in Japanese patients with Crohn's disease
- (2011) Mamoru Watanabe et al. Journal of Crohns & Colitis
- Randomised clinical trial: certolizumab pegol for fistulas in Crohn’s disease - subgroup results from a placebo-controlled study
- (2010) S. Schreiber et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Certolizumab Pegol in Patients With Moderate to Severe Crohn's Disease and Secondary Failure to Infliximab
- (2010) William J. Sandborn et al. Clinical Gastroenterology and Hepatology
- Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease
- (2010) Jean Frédéric Colombel et al. NEW ENGLAND JOURNAL OF MEDICINE
Find the ideal target journal for your manuscript
Explore over 38,000 international journals covering a vast array of academic fields.
SearchAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now